医学
SMAD公司
信号转导
肾
肾脏疾病
足细胞
糖尿病
中医药
转化生长因子
糖尿病肾病
癌症研究
内科学
药理学
内分泌学
病理
细胞生物学
生物
蛋白尿
替代医学
作者
Yan-Xu Chen,Xiaoxue Jiang,Qinyuan Zhang,Changqing Xu,Yao-Mu Hu,Caiyun Jin,Bo-Ling Zhang,Yao-Qin Fu,Zhi-Sheng Jin
出处
期刊:PubMed
[National Institutes of Health]
日期:2023-05-01
卷期号:48 (10): 2630-2638
被引量:2
标识
DOI:10.19540/j.cnki.cjcmm.20221114.401
摘要
Diabetic kidney disease is an important microvascular complication of diabetes and the leading cause of end-stage renal disease. Its pathological characteristics mainly include epithelial mesenchymal transition(EMT) in glomerulus, podocyte apoptosis and autophagy, and damage of glomerular filtration barrier. Transforming growth factor-β(TGF-β)/Smad signaling pathway is specifically regulated by a variety of mechanisms, and is a classic pathway involved in physiological activities such as apoptosis, proliferation and differentiation. At present, many studies have found that TGF-β/Smad signaling pathway plays a key role in the pathogenesis of diabetic kidney disease. Traditional Chinese medicine has significant advantages in the treatment of diabetic kidney disease for its multi-component, multi-target and multi-pathway characteristics, and some traditional Chinese medicine extracts, traditional Chinese medicines and traditional Chinese medicine compound prescription improve the renal injury of diabetic kidney disease by regulating TGF-β/Smad signaling pathway. This study clarified the mechanism of TGF-β/Smad signaling pathway in diabetic kidney disease by expounding the relationship between the key targets of the pathway and diabetic kidney disease, and summarized the research progress of traditional Chinese medicine in the treatment of diabetic kidney disease by interfering with TGF-β/Smad signaling pathway in recent years, to provide reference for drug research and clinical treatment of diabetic kidney disease in the future.
科研通智能强力驱动
Strongly Powered by AbleSci AI